MDXG
MIMEDX GROUP, INC.
$3.79
+4.12%
$542.2M
No data for this timeframe.
Vol
Market Cap$542.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders8 funds
Inst. Value$84.8M
Inst. Activity3 buys / 0 sells
Reddit Sentiment67° Warm
SEC Reports3
Recent Activity
Apr 29, 2026
SEC
MiMedx Group filed a DEFA14A (additional definitive proxy soliciting materials). The substantive content of the filing i
DEFA14A — Impact 3/10
Apr 22, 2026
SEC
MiMedx Group announced it will report Q1 2026 earnings on April 29, 2026, after market close, followed by a webcast and
PRESS-RELEASE — Impact 3/10
Apr 16, 2026
SEC
MiMedx Group announced a cost reduction initiative including the elimination of the Chief Operating Officer position and
8-K — Impact 7/10
Mar 13, 2026
Insider
Hulse William Frank IV sold 20,245 shares
General Counsel and CAO @ $4.38 ($88.7K)
Mar 13, 2026
Insider
Maersk-Moller Kimberly sold 6,762 shares
Chief Commercial Officer @ $4.38 ($29.6K)
Mar 10, 2026
Insider
Hulse William Frank IV sold 61,460 shares
General Counsel and CAO @ $4.50 ($276.6K)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
218,935 shares ($1.5M)
Inst.
WELLS FARGO & COMPANY/MN — ADD
135,404 shares ($916.7K)
Price Targets
$6.50
+71.5% upside
Strong Buy
Current $3.79
Low $5.00
Median $6.00
High $8.00
6 analysts
$5.00
$8.00
Analyst Ratings
2Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 30, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Apr 20, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Apr 17, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
| Feb 23, 2026 | Citizens | INITIATE | Market Outperform |
| Feb 17, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.03 ▼ -244.4% | $-0.04 — $-0.03 | -133% YoY | 4 |
| Next Q | $-0.00 ▼ -105.0% | $-0.01 — $0.01 | -102% YoY | 4 |
| Current FY | $-0.07 ▼ -157.7% | $-0.09 — $-0.03 | -117% YoY | 4 |
| Next FY | $0.12 ▼ -52.4% | $0.06 — $0.19 | 263% YoY | 4 |
Latest Reports
NEUTRAL
DEFA14A
3/10
MiMedx Group filed a DEFA14A (additional definitive proxy soliciting materials). The substantive content of the filing i
Apr 29, 2026
NEUTRAL
PRESS-RELEASE
3/10
MiMedx Group announced it will report Q1 2026 earnings on April 29, 2026, after market close, followed by a webcast and
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $48.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $16.7M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $8.3M | NEW |
| MORGAN STANLEY | $4.9M | TRIM |
| BANK OF AMERICA CORP | $3.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 13, 2026 | Hulse William | F | $88.7K |
| Mar 13, 2026 | Maersk-Moller Kimberly | F | $29.6K |
| Mar 10, 2026 | Hulse William | F | $276.6K |
| Mar 10, 2026 | DOUG RICE | F | $433.6K |
| Mar 10, 2026 | DOUG RICE | M | $1.1M |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $84.8M total value (12,520,951 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, CHARLES. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 7,184,262 | $48.6M | 57.4% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 2,467,065 | $16.7M | 19.7% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,219,589 | $8.3M | 9.7% | NEW |
| 4 | MORGAN STANLEY | 727,783 | $4.9M | 5.8% | TRIM -29.3% |
| 5 | BANK OF AMERICA CORP /DE/ | 483,668 | $3.3M | 3.9% | — |
| 6 | TWO SIGMA INVESTMENTS, LP | 218,935 | $1.5M | 1.7% | DOUBLED +259.7% |
| 7 | WELLS FARGO & COMPANY/MN | 135,404 | $916.7K | 1.1% | ADD +28.3% |
| 8 | FMR LLC | 84,245 | $570.3K | 0.7% | ADD +31.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 60,861 | 218,935 | +259.7% | $1.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 105,507 | 135,404 | +28.3% | $916.7K | 2025-Q4 |
| FMR LLC | ADD | 63,903 | 84,245 | +31.8% | $570.3K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,060,184 | 749,756 | -29.3% | $5.2M | 2025-Q3 |
| UBS Group AG | ADD | 449,887 | 586,777 | +30.4% | $4.1M | 2025-Q3 |
| FMR LLC | DOUBLED | 25,902 | 63,903 | +146.7% | $446.0K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 102,882 | 60,861 | -40.8% | $424.8K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 324,844 | 102,882 | -68.3% | $628.6K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 135,889 | 92,975 | -31.6% | $568.1K | 2025-Q2 |
| FMR LLC | DOUBLED | 5,928 | 25,902 | +336.9% | $158.3K | 2025-Q2 |
| UBS Group AG | TRIM | 525,913 | 378,424 | -28.0% | $2.9M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 70,047 | 135,889 | +94.0% | $1.0M | 2025-Q1 |
| NORGES BANK | EXIT | 417,900 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | ADD | 279,768 | 525,913 | +88.0% | $5.1M | 2024-Q4 |
| NORGES BANK | DOUBLED | 70,400 | 417,900 | +493.6% | $4.0M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 180,642 | 70,047 | -61.2% | $673.9K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,435,397 | — | $8.5M | 2024-Q3 |
5 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | Hulse William Frank IV | General Counsel and CAO | F | 20,245 | $4.38 | $88.7K |
| Mar 13, 2026 | Maersk-Moller Kimberly | Chief Commercial Officer | F | 6,762 | $4.38 | $29.6K |
| Mar 10, 2026 | Hulse William Frank IV | General Counsel and CAO | F | 61,460 | $4.50 | $276.6K |
| Mar 10, 2026 | DOUG RICE | Chief Financial Officer | F | 96,363 | $4.50 | $433.6K |
| Mar 10, 2026 | DOUG RICE | Chief Financial Officer | M | 243,000 | $4.50 | $1.1M |
| Mar 10, 2026 | Hulse William Frank IV | General Counsel and CAO | M | 136,364 | $4.50 | $613.6K |
| Mar 10, 2026 | Maersk-Moller Kimberly | Chief Commercial Officer | M | 42,845 | $4.50 | $192.8K |
| Mar 10, 2026 | Maersk-Moller Kimberly | Chief Commercial Officer | F | 21,270 | $4.50 | $95.7K |
| Mar 4, 2026 | Maersk-Moller Kimberly | Chief Commercial Officer | A | 74,163 | $0.00 | $0.00 |
| Mar 4, 2026 | Whitlow Ricci S | Chief Operating Officer | A | 74,163 | $0.00 | $0.00 |
| Mar 4, 2026 | Whitlow Ricci S | Chief Operating Officer | A | 62,068 | $0.00 | $0.00 |
| Mar 4, 2026 | Hulse William Frank IV | General Counsel and CAO | A | 74,987 | $0.00 | $0.00 |
| Mar 4, 2026 | DOUG RICE | Chief Financial Officer | A | 74,163 | $0.00 | $0.00 |
| Mar 4, 2026 | DOUG RICE | Chief Financial Officer | A | 62,068 | $0.00 | $0.00 |
| Mar 4, 2026 | Capper Joseph H | Chief Executive Officer | A | 371,094 | $0.00 | $0.00 |
| Mar 4, 2026 | Capper Joseph H | Chief Executive Officer | A | 310,574 | $0.00 | $0.00 |
| Mar 4, 2026 | Maersk-Moller Kimberly | Chief Commercial Officer | A | 62,068 | $0.00 | $0.00 |
| Mar 4, 2026 | Hulse William Frank IV | General Counsel and CAO | A | 62,758 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
DEFA14A
3/10
MiMedx Group filed a DEFA14A (additional definitive proxy soliciting materials). The substantive con
Apr 29, 2026
NEUTRAL
PRESS-RELEASE
3/10
MiMedx Group announced it will report Q1 2026 earnings on April 29, 2026, after market close, follow
Apr 22, 2026
BEARISH
8-K
7/10
MiMedx Group announced a cost reduction initiative including the elimination of the Chief Operating
Apr 16, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 2 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.50 mean target
+71.5% upside
Strong Buy (1.17)
$5.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $3.79 |
| Target Low | $5.00 |
| Target Mean | $6.50 |
| Target Median | $6.00 |
| Target High | $8.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.03 | $-0.04 | $-0.03 | -132.5% | -244.4% | 0↑ 2↓ | $0.1B | -36.1% | 4 |
| Next Q 2026-09-30 |
$-0.00 | $-0.01 | $0.01 | -101.7% | -105.0% | 0↑ 2↓ | $0.1B | -37.8% | 4 |
| Current FY 2026-12-31 |
$-0.07 | $-0.09 | $-0.03 | -116.7% | -157.7% | 0↑ 2↓ | $0.3B | -35.8% | 4 |
| Next FY 2027-12-31 |
$0.12 | $0.06 | $0.19 | 263.3% | -52.4% | 0↑ 2↓ | $0.3B | 12.4% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.033 | |
| 7d ago | $-0.003 | -0.030 |
| 30d ago | $0.022 | -0.055 |
| 60d ago | $0.022 | -0.055 |
| 90d ago | $0.020 | -0.053 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 30, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 20, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 17, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Feb 23, 2026 | Citizens | INITIATE | — | Market Outperform |
| Feb 17, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
5 Deep-Value Stocks Under $5 🔎
▲ 1
💬 1
⚡ 0.5
May 8, 2026
other
MIMEDX Announces Launch of G4Derm® Plus
<p align="center"><em>Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio</em></p>
May 1, 2026
short_volume
Short Volume: MDXG — 61.8% short (0.6M / 1.0M)
Short: 642,283 | Exempt: 516 | TRF Vol: 1,038,639 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
short_interest
FTD: MDXG — 751,372 shares ($2.3M) failed to deliver
Settlement: 20260430, Price: $3.09, FTD Value: $2,321,739.48, MIMEDX GROUP, INC (US)
Apr 29, 2026
earnings_calendar
MDXG Q1 2026 Earnings Scheduled — 2026-04-29
Apr 29, 2026
short_volume
Short Volume: MDXG — 70.5% short (0.9M / 1.2M)
Short: 875,900 | Exempt: 1,208 | TRF Vol: 1,241,740 | Short Ratio: 70.5% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
short_volume
Short Volume: MDXG — 57.6% short (0.5M / 0.8M)
Short: 489,287 | Exempt: 1,000 | TRF Vol: 849,652 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
earnings
MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
<p>MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will repo
Apr 21, 2026
short_volume
Short Volume: MDXG — 57.4% short (0.4M / 0.7M)
Short: 429,458 | Exempt: 539 | TRF Vol: 748,385 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: MDXG — 55.1% short (0.6M / 1.1M)
Short: 584,031 | Exempt: 511 | TRF Vol: 1,060,186 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
other
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
<p align="center"><em>Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes</em></p>
Apr 1, 2026
short_interest
FTD: MDXG — 253,964 shares ($1.0M) failed to deliver
Settlement: 20260401, Price: $3.95, FTD Value: $1,003,157.8, MIMEDX GROUP, INC (US)
Mar 23, 2026
other
MIMEDX Announces Launch of CHORIOFIX™
Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products <pre>Further Expands Company’s Broad Portfolio of Advanced Wound Car
Mar 5, 2026
other
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
Bolsters Surgical offering with product specifically designed for use in endocrine procedures <pre>Bolsters Surgical offering with product specificall
Feb 25, 2026
earnings_calendar
MDXG Q4 2025 Earnings After Market Close — 2026-02-25